MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Market Cap 2011-2026 | ZOM
As of May 01, 2026 Zomedica Corp. has a market cap of $ 98 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 137 M | 245 M | 297 M | 335 M | 25.9 M | 80.6 M | 175 M | 200 K | 200 K | 68 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 335 M | 68 K | 130 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
3.63 B | $ 2.67 | 3.49 % | $ 1.37 B |  Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Harrow Health
HROW
|
1.93 B | $ 40.53 | 0.72 % | $ 1.49 B | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 4.19 | -0.48 % | $ 58.9 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
2.36 M | - | - | $ 33.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
3.38 B | $ 5.72 | 2.33 % | $ 2.09 B | Canada |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 1.11 | 1.83 % | $ 119 M | Canada |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.41 | 2.92 % | $ 402 M | Canada |
 |
Evolus
EOLS
|
271 M | $ 5.39 | 4.05 % | $ 347 M | USA |
 |
Sundial Growers
SNDL
|
889 K | $ 1.36 | 3.42 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.23 | 3.0 % | $ 421 M | USA |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.35 | 2.17 % | $ 309 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 25.49 | 1.39 % | $ 1.18 B | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 18.43 | 2.11 % | $ 118 M | USA |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
623 M | $ 7.26 | 2.98 % | $ 635 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 1.1 | 3.77 % | $ 1.37 M | USA |
 |
Relmada Therapeutics
RLMD
|
247 M | $ 7.52 | 2.04 % | $ 297 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tilray
TLRY
|
1.19 B | $ 6.24 | 1.63 % | $ 3.86 B | Canada |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.93 | -0.46 % | $ 46.4 M | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
Veru
VERU
|
108 M | $ 2.25 | 0.45 % | $ 303 M | USA |
 |
Viatris
VTRS
|
18.4 B | $ 14.94 | -0.2 % | $ 17.9 B | USA |
 |
Aurora Cannabis
ACB
|
915 M | $ 3.44 | 4.56 % | $ 86.3 M | Canada |
 |
cbdMD
YCBD
|
1.68 M | $ 0.87 | 0.15 % | $ 3.75 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
33.8 M | $ 0.88 | -2.56 % | $ 31.7 M | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
2.75 M | $ 0.54 | -1.78 % | $ 2.32 M |  China |
 |
TherapeuticsMD
TXMD
|
23 M | $ 2.04 | -3.32 % | $ 23.6 M | USA |